Subcutaneous immunoglobulin therapy in pediatric primary antibody deficiency

Pediatric Health

Volumn 3, Issue 3, 2009, Pages 231-240

  Moore, Meredith L ^a   Quinn, James M ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Hypogammaglobulinemia; Immune deficiency; Immunodeficiency; Intravenous immunoglobulin; Primary antibody deficiency; SCIG; Subcutaneous immunoglobulin

Indexed keywords

GAMMANORM; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; SUBCUVIA; SUBGAM; UNCLASSIFIED DRUG;

AGAMMAGLOBULINEMIA; ANAPHYLAXIS; BACKACHE; BACTERIAL INFECTION; CHILL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHEMA; FATIGUE; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; PATIENT SATISFACTION; PREVALENCE; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SWELLING; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 70349637681     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/phe.09.17     Document Type: Review

References (55)

1. Lindegren ML, Kobrynski L, Rasmussen SA et al.: Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm. Rep. 53(RR-1), 1-29 (2004).
2. Baumgart KW, Britton WJ, Kemp A, French M, Roberton D: The spectrum of primary immunodeficiency disorders in Australia. J. Allergy Clin. Immunol. 100(3), 415-423 (1997).
3. Boyle JM, Buckley RH: Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J. Clin. Immunol. 27(5), 497-502 (2007).
4. Berger M: A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr. Allergy Asthma Rep. 2(5), 368-378 (2002).
5. Good RA, Lorenz E: Historic aspects of intravenous immunoglobulin therapy. Cancer 68(6 Suppl.), 1415-1421 (1991).
6. Bruton OC: Agammaglobulinemia. Pediatrics 9(6), 722-728 (1952).
7. Gitlin D, Janeway CA: Agammaglobulinemia, congenital, acquired and transient forms. Prog. Hematol. 1, 318-329 (1956).
8. Stiehm ER: Standard and special human immune serum globulins as therapeutic agents. Pediatrics 63(2), 301-319 (1979).
9. Berger M, Cupps TR, Fauci AS: Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann. Intern. Med. 93(1), 55-56 (1980).
10. Ugazio AG, Duse M, Re R, Mangili G, Burgio GR: Subcutaneous infusion of gammaglobulins in management of agammaglobulinaemia. Lancet 1(8265), 226 (1982).
11. Roord JJ, van der Meer JW, Kuis W et al.: Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin. Lancet 1(8273), 689-690 (1982).
12. Cunningham-Rundles C, Siegal FP, Smithwick EM et al.: Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann. Intern. Med. 101(4), 435-439 (1984).
13. Misbah SA, Chapel HM: Adverse effects of intravenous immunoglobulin. Drug Saf. 9(4), 254-262 (1993).
14. Orange JS, Hossny EM, Weiler CR et al.: Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117(4 Suppl.), S525-553 (2006).
15. Gardulf A: Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 21(2), 105-116 (2007).
16. Gregori L, Maring JA, MacAuley C et al.: Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 32(1), 1-10 (2004).
17. Poelsler G, Berting A, Kindermann J et al.: A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang. 94(3), 184-192 (2008).
18. Trejo SR, Hotta JA, Lebing W et al.: Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang. 84(3), 176-187 (2003).
19. Ochs HD, Fischer SH, Wedgwood RJ: Modified immune globulin: its use in the prophylactic treatment of patients with immune deficiency. J. Clin. Immunol. 2(2 Suppl), 22S-30S (1982).
20. Ochs HD, Fischer SH, Wedgwood RJ et al.: Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am. J. Med. 76(3A), 78-82 (1984).
21. Bonilla FA: Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol. Allergy Clin. N. Am. 28(4), 803-819, ix (2008).
22. Gardulf A, Nicolay U, Math D et al.: Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J. Allergy Clin. Immunol. 114(4), 936-942 (2004).
23. Smith GN, Griffiths B, Mollison D, Mollison PL: Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1(7762), 1208-1212 (1972).
24. Remvig L, Andersen V, Hansen NE, Karle H: Prophylactic effect of self-administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: a triple-blind cross-over study comparing P-IgG levels of 3 g l-1 versus 6 g l-1. J. Intern. Med. 229(1), 73-77 (1991).
25. Vivaglobin®, package insert. ZLB Behring, Marburg, Germany, 2007.
26. Gardulf A, Hammarstrom L, Smith CI: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338(8760), 162-166 (1991).
27. Gardulf A, Nicolay U, Asensio O et al.: Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J. Clin. Immunol. 26(2), 177-185 (2006).
28. Radinsky S, Bonagura VR: Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J. Allergy Clin. Immunol. 112(3), 630-633 (2003).
29. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J. Clin. Immunol. 20(2), 94-100 (2000).
30. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M: Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J. Clin. Immunol. 26(3), 265-273 (2006).
31. Eijkhout HW, van Der Meer JW, Kallenberg CG et al.: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann. Intern. Med. 135(3), 165-174 (2001).
32. Ochs HD, Pinciaro PJ: Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J. Clin. Immunol. 24(3), 309-314 (2004).
33. Pac M, Bernatowska E: Polish experience with immunoglobulin replacement treatment by subcutaneous infusion. Centr. Eur. J. Immunol. 30(3-4), 78-82 (2005).
34. Fasth A, Nystrom J: Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta. Paediatr. 96(10), 1474-1478 (2007).
35. Ballow M: Safety of IGIV therapy and infusion-related adverse events. Immunol. Res. 38(1-3), 122-132 (2007).
36. Ballow M, Berger M, Bonilla FA et al.: Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 84(3), 202-210 (2003).
37. Schiff RI, Williams LW, Nelson RP, Buckley RH, Burks W, Good RA: Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J. Clin. Immunol. 17(1), 21-28 (1997).
38. Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI: Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency 4(1-4), 81-84 (1993).
39. Gardulf A, Andersen V, Bjorkander J et al.: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345(8946), 365-369 (1995).
40. Hansen S, Gustafson R, Smith CI, Gardulf A: Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin. Immunol. 104(3), 237-241 (2002).
41. Abrahamsen TG, Sandersen H, Bustnes A: Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 98(6 Pt 1), 1127-1131 (1996).
42. Thomas MJ, Brennan VM, Chapel HH: Rapid subcutaneous immunoglobulin infusions in children. Lancet 342(8884), 1432-1433 (1993).
43. Gaspar J, Gerritsen B, Jones A: Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch. Dis. Child. 79(1), 48-51 (1998).
44. Nicolay U, Kiessling P, Berger M et al.: Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J. Clin. Immunol. 26(1), 65-72 (2006).
45. Hogy B, Keinecke HO, Borte M: Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur. J. Health Econ. 6(1), 24-29 (2005).
46. Membe SK, Ho C, Cimon K, Morrison A, Kanani A, Roifman CM: Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol. Allergy Clin. N. Am. 28(4), 861-874, x (2008).
47. Berger M: Subcutaneous administration of IgG. Immunol. Allergy Clin. N. Am. 28(4), 779-802, viii (2008).
48. Fasth A, Nystrom J: Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J. Clin. Immunol. 28(4), 370-378 (2008).
49. Stiehm ER, Casillas AM, Finkelstein JZ et al.: Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J. Allergy Clin. Immunol. 101(6 Pt 1), 848-849 (1998).
50. MacLeish S, Hostoffer R: Subcutaneous Versus Intravenous immunoglobulin for the treatment of DiGeorge syndrome related hypogammaglobulinemia. J. Allergy Clin. Immunol. 117(2), S174 (2006).
51. Arora R, Newton TC, Nelson MR: Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease. Ann. Allergy Asthma Immunol. 99(4), 367-370 (2007).
52. Eijkhout HW, van den Broek PJ, van der Meer JW: Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth. J. Med. 61(6), 213-217 (2003).
53. Sundin U, Nava S, Hammarstrom L: Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin. Exp. Immunol. 112(2), 341-346 (1998).
54. Waniewski J, Gardulf A, Hammarstrom L: Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J. Clin. Immunol. 14(2), 90-97 (1994).
55. Bohle MV, Burton J, Chapel HM: Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy. Immunol. Allergy Clin. N. Am. 28(4), 821-832 (2008).